Light-Activated ointment shows promise for rare skin cancer
NCT ID NCT05872854
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a synthetic ointment (HyBryte) activated by visible light to treat mycosis fungoides, a type of skin lymphoma. Ten adults with early-stage disease received treatment for up to 54 weeks. The goal was to see if the ointment could reduce redness, scaling, and plaque thickness on the skin.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, 19034, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A microchip implanted in tumors could reveal which drugs work best
- Skin gel targets immune signals in rare lymphoma
- Could an ALS drug clear the fog of chemo brain?
- Combination therapy aims to boost response in rare skin cancers
- Can a tailored exercise and diet plan beat cancer fatigue?
- New cream targets skin lymphoma without steroids